CARFLIEVA 30MG (Carfilzomib for Injection 30mg) is a specialized anticancer medicine used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. It contains Carfilzomib, a highly effective proteasome inhibitor that helps slow down and control the growth of cancer cells in the body. This oncology injection is commonly prescribed by healthcare professionals as part of advanced chemotherapy and targeted cancer treatment protocols.

Multiple myeloma develops when abnormal plasma cells multiply uncontrollably inside the bone marrow. These cancerous cells interfere with the normal production of blood cells and can weaken bones, reduce immunity, and affect kidney function. CARFLIEVA 30MG works by targeting and blocking proteasomes, which are responsible for breaking down proteins inside cancer cells. When proteasomes are inhibited, cancer cells accumulate damaged proteins and eventually die, helping reduce the spread of the disease.

CARFLIEVA 30MG is widely used in modern oncology treatment because of its effectiveness in managing relapsed or refractory multiple myeloma. It is often prescribed for patients who have previously received other cancer therapies but require further treatment support due to disease progression or recurrence. Doctors may use this medicine alone or in combination with other anticancer medicines depending on the patient’s condition and treatment plan.

This Carfilzomib injection is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and reliable clinical performance. The medicine is intended for hospital and oncology center use and should only be administered by trained healthcare professionals under proper medical supervision.

Patients receiving CARFLIEVA 30MG usually undergo regular medical monitoring, blood tests, and health assessments during treatment to help improve treatment outcomes and reduce the risk of complications. Oncology specialists carefully determine the dosage and treatment schedule based on the patient’s overall health, response to therapy, and stage of cancer.

Due to its advanced mechanism of action and targeted cancer therapy approach, CARFLIEVA 30MG has become an important medicine in the management of multiple myeloma and modern hematology-oncology treatment protocols.

CARFLIEVA 30MG (Carfilzomib for Injection 30mg) is primarily used in the treatment and management of multiple myeloma and related oncology conditions. It is considered an important targeted therapy medicine in hematology and cancer care.

Common Uses of CARFLIEVA 30MG

1. Treatment of Multiple Myeloma

CARFLIEVA 30MG is mainly used for the treatment of multiple myeloma, a cancer affecting plasma cells in the bone marrow.

2. Relapsed Multiple Myeloma

Doctors may prescribe Carfilzomib Injection for patients whose cancer has returned after previous treatment.

3. Refractory Multiple Myeloma

This medicine is also used in patients whose multiple myeloma no longer responds effectively to certain previous cancer therapies.

4. Combination Oncology Therapy

CARFLIEVA may be used in combination with other anticancer medicines and corticosteroids to improve treatment response.

5. Advanced Hematology Treatment

The injection is commonly included in advanced hematology-oncology treatment protocols for blood cancer management.

6. Cancer Cell Growth Control

Carfilzomib helps slow down the growth and survival of abnormal plasma cells by targeting cellular protein regulation mechanisms.

---

How CARFLIEVA 30MG Works

Carfilzomib belongs to a class of medicines known as proteasome inhibitors. Proteasomes help cancer cells remove damaged proteins and continue growing.

CARFLIEVA works by:

    • Blocking proteasome activity

    • Preventing cancer cell survival

    • Causing accumulation of damaged proteins

    • Triggering cancer cell death

    • Helping control the progression of multiple myeloma

This targeted mechanism makes Carfilzomib an effective medicine in advanced blood cancer treatment.

Like other anticancer medicines, CARFLIEVA 30MG may cause side effects in some patients. Side effects may vary depending on the patient’s health condition, dosage, and response to treatment.

Common Side Effects

1. Fatigue and Weakness

Patients may experience tiredness, low energy, or weakness during treatment.

2. Fever

Mild to moderate fever may occur after receiving the injection.

3. Nausea and Vomiting

Digestive discomfort, nausea, or vomiting may develop in certain patients.

4. Shortness of Breath

Some individuals may experience breathing discomfort during treatment.

5. Low Blood Cell Counts

CARFLIEVA may reduce blood cell production, leading to:

    • Low white blood cell count

    • Low platelet count

    • Anemia

6. Diarrhea or Constipation

Digestive system-related side effects may occasionally occur.

7. Swelling

Fluid retention or swelling in the legs, hands, or feet may develop in some cases.

8. Muscle Pain

Patients may experience muscle cramps or body pain during therapy.

9. Loss of Appetite

Reduced appetite and weakness may occur during oncology treatment.

---

Serious Side Effects

Some serious side effects may require immediate medical attention.

Seek Medical Help If You Experience:

    • Chest pain

    • Severe breathing difficulty

    • Severe infection symptoms

    • Unusual bleeding or bruising

    • Sudden swelling

    • Severe allergic reactions

    • Kidney-related problems

    • High fever or chills

Patients should immediately contact their doctor if severe symptoms develop during treatment.

The dosage of CARFLIEVA 30MG (Carfilzomib for Injection 30mg) is determined by a qualified healthcare professional based on the patient’s medical condition and treatment requirements.

Factors Affecting Dosage

1. Stage of Multiple Myeloma

Dosage may vary depending on the severity and progression of the disease.

2. Body Weight and Overall Health

Doctors calculate dosage according to the patient’s body condition and treatment tolerance.

3. Previous Cancer Treatments

Prior chemotherapy or oncology therapies may influence dosage planning.

4. Response to Treatment

Doctors may adjust the dosage depending on treatment response and side effects.

---

Administration Method

CARFLIEVA 30MG is administered:

    • Through intravenous infusion (IV)

    • By trained healthcare professionals

    • In hospitals or oncology centers

    • Under strict medical supervision

Patients should never self-administer this medicine.

---

Important Dosage Guidelines

    • Follow the doctor’s treatment schedule carefully

    • Regular blood tests may be required

    • Hydration may be recommended before treatment

    • Inform your doctor about side effects immediately

    • Do not miss scheduled treatment sessions

---

Precautions Before Using CARFLIEVA 30MG

Before starting treatment, patients should inform their doctor if they have:

    • Heart disease

    • Kidney problems

    • Liver disorders

    • High blood pressure

    • Breathing problems

    • Active infections

Patients should also disclose all ongoing medicines and supplements to avoid potential drug interactions.

---

Storage Instructions

    • Store in a cool and dry place

    • Protect from direct sunlight

    • Keep away from moisture

    • Keep out of reach of children

    • Use only under medical supervision

---

Why Choose CARFLIEVA 30MG?

    • Advanced targeted therapy for multiple myeloma

    • High-quality pharmaceutical formulation

    • Effective proteasome inhibitor

    • Reliable oncology treatment support

    • Manufactured under strict quality standards

    • Suitable for modern hematology-oncology protocols

---

Frequently Asked Questions (FAQs)

What is CARFLIEVA 30MG used for?

It is mainly used for the treatment of multiple myeloma, a type of blood cancer affecting plasma cells.

What is Carfilzomib?

Carfilzomib is a proteasome inhibitor used in targeted cancer therapy for multiple myeloma treatment.

Is CARFLIEVA a chemotherapy medicine?

It is considered a targeted anticancer therapy used in oncology treatment programs.

How is CARFLIEVA 30MG administered?

The medicine is given intravenously by trained healthcare professionals in hospitals or oncology centers.

Can CARFLIEVA cause weakness or fatigue?

Yes, weakness and tiredness are common side effects during treatment.

Is regular monitoring necessary during treatment?

Yes, patients usually require regular blood tests and medical monitoring.

Can patients use this medicine at home?

No, this injection should only be administered under medical supervision.

Should patients consult a doctor before starting treatment?

Yes, this medicine should always be used strictly under the guidance of qualified healthcare professionals.